Public invited to stem cell event in San Diego April 20 – The San Diego Union-Tribune
The San Diego Union-Tribune |
Public invited to stem cell event in San Diego April 20
The San Diego Union-Tribune Stem cell cures are real, and more are on the way. That’s part of the message California’s stem cell agency will deliver in a special patient advocate event in La Jolla on Thursday, April 20. To be held from noon to 1 p.m., the California Institute for … |
The San Diego Union-Tribune |
California’s stem cell agency invites public to San Diego event April 20
The San Diego Union-Tribune Clinical trials are risky and rely on brave pioneers who are willing to put their bodies on the line to help test the safety and effectiveness of potential new therapies. At its December 2016 meeting, the governing Board of the California Institute for … |
NewHampshire.com |
Stem cell donor registry drive seeks to help retired Brookline teacher
NewHampshire.com Multiple myeloma is a plasma cell disorder that attacks cells in a person’s bone marrow. Since traditional treatments are not working for Kathi Bond, doctors are now looking for radical ways to preserve her life, and a donor transplant is the next … |
OncLive |
Dr. Costin on Frontline Immunotherapy for Patients With NSCLC
OncLive Daniel Costin, MD, hematology and oncology, White Plains Hospital, discusses the potential with immunotherapy agents in the frontline setting as treatment for patients with non–small cell lung cancer (NSCLC). Immunotherapy has become a standard of care … |
|
Foundation Medicine Mining Clinical Sequencing Data for New Determinants of Immunotherapy Response
GenomeWeb As immunotherapy has rapidly gained ground in the oncology community, research has accelerated in tandem to identify molecular markers or signatures that can best predict which patients may benefit. “It likely hasn’t escaped the attention of [attendees … |
Seeking Alpha |
Juno: How Can CAR–T’s Big Loser Still Be Worth $2.5B?
Seeking Alpha Novartis and Kite submitted applications to the FDA in March for Chimeric Antigen Receptor Engineered T cells targeting CD19 positive B cell leukemia and lymphoma, respectively. What would have been a Juno Therapeutics CD19 CAR-T candidate for … |